Research and Markets View this Complete and Systematic Description of Past Present and Future Efforts in Breast Cancer RD



April 18 2005 Research and Markets httpwwwresearchandmarketscomreportsc15834 has announced the addition of Basic Platform Report Breast Cancer to their offering Basic Platform Report Breast Cancer provides a complete and systematic description of the past present and future efforts in cancer RD focused on the breast cancer field Structured and defined information necessary to analyze the breast cancer drug candidates currently under development has been identified More than 150 industry related RD strategies have been identified Several thousands of records from a multitude of sources build the structure and content of this report The report is divided in 6 sections each section structured to enable the study of a specific topic Section I Investigators Section II Drug candidates Section III Developmental stage Section IV Therapeutic types Section V Mechanism of action targets Section VI Drug effects Basic Platform Report Breast Cancer is a unique gathering of information found no were else The information structure will provide an easy reading format to track B2B collaborations and industry academic relationships as well as identify candidates receiving Fast Track Designations and Orphan Drug Status Example of candidates included The complete number of candidate drugs in clinical research for breast cancer are more than 150 and some of them are listed below Abraxane Alimta Arimidex Aromasin Avastin BMS21738001 BMS247550 CAELYX CCI779 Faslodex Femara Fenretinide Gleevec GTI2040 Herceptin Iressa ISIS2503 Lapatinib Nolvadex Sarasar SDX105 Tarceva Theratope Velcade Zarnestra Zoladex ZD0473 and many other that are in an earlier stage of development Example of companies included More than 170 companies have been identified within the sphere of breast cancer and the biggest players within this field are listed below American Bioscience AnorMED AstraZeneca Biomira Inc BristolMyers Squibb Eli Lilly and Company Genentech GlaxoSmithKline ISIS Pharmaceuticals Johnson and Johnson Lorus Therapeutics McNeil Pharmaceuticals Merck KgaA Millennium Pharmaceuticals NeoRx Novartis OSI Pharmaceuticals Pfizer Roche Salmedix ScheringPlough and Wyeth The report will assist you in Tracking cutting edge companies therapies and new technologies Rapid identification of promising drug candidates and future partners competitors Fast identification of inlicensing opportunities Laying down a comprehensive framework for further analysis of the breast targeting field Producing presentations surrounding the development of cancer therapeutics Identifying novel breast cancer targeting agents For more information visit httpwwwresearchandmarketscomreportsc15834 Laura Wood Senior Manager Research and Markets email protected from spam bots Fax +353 1 4100 980



Research and Markets View this Complete and Systematic Description of Past Present and Future Efforts in Breast Cancer RD